Edwards Lifesciences (EW) traded lower Thursday, extending recent pressure as the market refocused on the pace of growth in the company’s transcatheter aortic valve replacement (TAVR) business and the near-term margin tradeoff from continued investment spending. With the next earnings update less than two weeks away, traders appeared to de-risk into the print, driving the shares down roughly 3% on the session.

The next key checkpoint is Edwards’ first-quarter earnings report scheduled for April 23, 2026, which is set to refresh investor visibility on 2026 growth and margin execution. Management has recently reiterated confidence in its 2026 outlook, including 6%–8% TAVR growth commentary made at healthcare conferences, keeping expectations elevated heading into the upcoming quarter’s numbers.

Edwards is navigating a transition year where investors want evidence that procedure growth is durable while operating leverage improves. Recent conference commentary has highlighted targeted profitability improvements (including operating margin expansion ambitions) alongside ongoing product-cycle investments across structural heart, leaving the stock prone to pullbacks on any hint that volume or mix is tracking below plan.

Investors are looking for clearer confirmation that newer platforms and expansion opportunities can offset any deceleration in legacy growth rates, with attention on pipeline and commercialization milestones across mitral and tricuspid therapies. Separately, policy and guideline-related milestones later in 2026 are potential demand tailwinds, but the nearer-term stock direction is likely to be driven by April results and management’s tone on the full-year trajectory.